Novo Nordisk A/S
🇩🇰Denmark
- Country
- 🇩🇰Denmark
- Ownership
- Public
- Established
- 1923-01-01
- Employees
- 63.3K
- Market Cap
- $602.2B
- Website
- http://www.novonordisk.com
Within-subject Variability of Insulin Detemir in Children and Adolescents With Type 1 Diabetes
Phase 1
Completed
- Conditions
- DiabetesDiabetes Mellitus, Type 1
- Interventions
- First Posted Date
- 2011-12-22
- Last Posted Date
- 2017-01-30
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 32
- Registration Number
- NCT01497574
- Locations
- 🇩🇪
Novo Nordisk Investigational Site, Hannover, Germany
Pharmacokinetics of Insulin Detemir in Subjects With Type 2 Diabetes
Phase 1
Completed
- Conditions
- Diabetes Mellitus, Type 2Diabetes
- Interventions
- First Posted Date
- 2011-12-22
- Last Posted Date
- 2017-01-27
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 50
- Registration Number
- NCT01497600
- Locations
- 🇺🇸
Novo Nordisk Investigational Site, Chula Vista, California, United States
To Estimate the Percentage of Children and Adolescents in Tunisia With Acceptably Controlled Diabetes Mellitus Type 1
- First Posted Date
- 2011-12-16
- Last Posted Date
- 2017-01-19
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 402
- Registration Number
- NCT01493388
- Locations
- 🇹🇳
Novo Nordisk Investigational Site, Tunisia, Tunisia
Safety and Efficacy of Turoctocog Alfa in Prevention and Treatment of Bleeds in Previously Untreated Children With Haemophilia A
Phase 3
Completed
- Conditions
- Haemophilia ACongenital Bleeding Disorder
- Interventions
- First Posted Date
- 2011-12-16
- Last Posted Date
- 2020-11-30
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 60
- Registration Number
- NCT01493778
- Locations
- 🇹🇷
Novo Nordisk Investigational Site, Samsun, Turkey
Observational Study With InnoLet® in Daily Clinical Practice
Completed
- Conditions
- Diabetes Mellitus, Type 1DiabetesDiabetes Mellitus, Type 2
- Interventions
- First Posted Date
- 2011-12-15
- Last Posted Date
- 2017-02-28
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 1030
- Registration Number
- NCT01492959
- Locations
- 🇰🇷
Novo Nordisk Investigational Site, Seoul, Korea, Republic of
NovoLet® Surveillance Study on Using Human Insulin System in Indonesia
Completed
- Conditions
- DiabetesDiabetes Mellitus, Type 1Diabetes Mellitus, Type 2
- Interventions
- Drug: biphasic human insulinDrug: isophane human insulinDrug: human soluble insulin
- First Posted Date
- 2011-12-14
- Last Posted Date
- 2017-02-28
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 1981
- Registration Number
- NCT01492153
- Locations
- 🇮🇩
Novo Nordisk Investigational Site, Jakarta, Indonesia
Observational Study With Mixtard® 30 NovoLet® to Assess Patient Satisfaction
Completed
- Conditions
- DiabetesDiabetes Mellitus, Type 1Diabetes Mellitus, Type 2
- Interventions
- Drug: biphasic human insulin 30
- First Posted Date
- 2011-12-14
- Last Posted Date
- 2017-02-28
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 1330
- Registration Number
- NCT01492218
- Locations
- 🇵🇭
Novo Nordisk Investigational Site, Manilla, Philippines
Observational Study on Efficacy, Safety and Convenience of Using Mixtard® 30 NovoLet® Alone or Combined With OHA in Treatment of Type 2 Diabetes in Routine Clinical Practice
Completed
- Conditions
- Diabetes Mellitus, Type 2Diabetes
- Interventions
- Drug: biphasic human insulin 30
- First Posted Date
- 2011-12-14
- Last Posted Date
- 2016-12-13
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 1935
- Registration Number
- NCT01492166
- Locations
- 🇮🇩
Novo Nordisk Investigational Site, Jakarta, Indonesia
NovoLet® Acceptance Study Within the Hospital Practise in Indonesia
Completed
- Conditions
- Diabetes Mellitus, Type 1Diabetes Mellitus, Type 2Diabetes
- Interventions
- First Posted Date
- 2011-12-14
- Last Posted Date
- 2016-10-14
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 203
- Registration Number
- NCT01492205
- Locations
- 🇮🇩
Novo Nordisk Investigational Site, Jakarta, Indonesia
Single Dose Pharmacokinetics of Repaglinide, Metformin and Combination Tablet in Fed Healthy Volunteers
Phase 1
Completed
- Conditions
- DiabetesDiabetes Mellitus, Type 2
- Interventions
- First Posted Date
- 2011-12-13
- Last Posted Date
- 2017-02-10
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 93
- Registration Number
- NCT01490658
- Locations
- 🇺🇸
Novo Nordisk Investigational Site, Austin, Texas, United States
© Copyright 2025. All Rights Reserved by MedPath